key: cord-0869108-d2x0rb6u
authors: Lopez, Joseph A; Denkova, Martina; Ramanathan, Sudarshini; Dale, Russell C; Brilot, Fabienne
title: Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease
date: 2021-07-26
journal: Clin Transl Immunology
DOI: 10.1002/cti2.1316
sha: d0672b3338d2b33af78a1c1ca2bc41215f837759
doc_id: 869108
cord_uid: d2x0rb6u

Autoimmunity plays a significant role in the pathogenesis of demyelination. Multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) are now recognised as separate disease entities under the amalgam of human central nervous system demyelinating disorders. While these disorders share inherent similarities, investigations into their distinct clinical presentations and lesion pathologies have aided in differential diagnoses and understanding of disease pathogenesis. An interplay of various genetic and environmental factors contributes to each disease, many of which implicate an autoimmune response. The pivotal role of the adaptive immune system has been highlighted by the diagnostic autoantibodies in NMOSD and MOGAD, and the presence of autoreactive lymphocytes in MS lesions. While a number of autoantigens have been proposed in MS, recent emphasis on the contribution of B cells has shed new light on the well‐established understanding of T cell involvement in pathogenesis. This review aims to synthesise the clinical characteristics and pathological findings, discuss existing and emerging hypotheses regarding the aetiology of demyelination and evaluate recent pathogenicity studies involving T cells, B cells, and autoantibodies and their implications in human demyelination.

Central nervous system (CNS) demyelination occurs when the myelin responsible for the insulation of axons is damaged, resulting in poor conduction of action potentials, impaired neuronal signalling and, in some cases, partial or complete neuronal loss. Adaptive immunity enables a rapid and intensive response against subsequent exposures to previously encountered antigens. B and T lymphocytes are the key mediators of this branch of the immune system and are responsible for the humoral and cell-mediated adaptive immune response, respectively. Antibodies or immunoglobulins (Igs) are specialised proteins produced by B cells with a precise affinity and specificity for their target antigen. Historically, the brain and spinal cord were perceived as immuneprivileged sites, lacking the conventional lymphatic system accessible to the remainder of the body. 1 Recent decades have shed light upon the complexity of ongoing immune trafficking across the blood-brain and blood-cerebrospinal fluid (CSF) barriers. 2 This intricate interplay between the CNS and the immune system has highlighted the notion that certain neurological demyelinating disorders are attributable to an inflammatory autoimmune pathophysiology.

In this review, we explore the complex role of autoimmunity in CNS demyelinating disorders, namely multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Firstly, we investigate the similarities and differences in the clinical characteristics and pathologies between the three disease entities. We then consider hypotheses regarding the autoimmune aetiology of these disorders and the mechanisms involved in disease pathogenesis. Lastly, we discuss trends in the diagnosis and therapy of these disorders as well as future directions in the field of autoimmune demyelination.

Multiple sclerosis is a chronic inflammatory neurological disorder characterised by numerous white matter lesions or plaques throughout the CNS. The prevalence of MS is rising globally with an estimated 35.9 people per 100 000 affected by MS which varies significantly depending on geography and ethnicity. 3 Of those diagnosed with MS, there is a clear female preponderance with females 2-4 times as likely to be affected than males. 3 Relapsing-remitting MS (RRMS) is the most common form of the disease and involves the onset of symptoms that are alleviated during periods of recovery until an eventual subsequent attack. While some patients experience recovery from symptoms during remission phases, others persist with residual disability following attacks. 4 Relapse rates can vary, with reported annualised relapse rates of 0.27-1. 66 relapses per year in treatment-na€ ıve MS patients. 5 Between 50 and 80% of patients with RRMS develop debilitating symptoms which worsen in a progressive manner. 6 At this stage, relapsing-remitting patients are recognised as having transitioned to secondary progressive MS (SPMS). There are limited clinical and pathological indicators that identify the transition of RRMS to SPMS. 4 Approximately 15% of MS patients are diagnosed with primary progressive MS and experience persistent accumulation of neurological deficits from disease onset. 7 Disease-modifying therapeutics are often inefficacious at alleviating symptoms of the progressive forms of MS. 8 Diagnosis of MS has been achieved by expert consensus as defined by 2010 McDonald criteria and its subsequent revision in 2017 and particularly emphasises the clinical presentation of demyelinating episodes or attacks that are disseminated in space and time. 9 These episodes are complemented by paraclinical findings of typical white matter lesions observed using magnetic resonance imaging (MRI), abnormalities in visually evoked potentials (VEPs) which evaluate the function of visual pathways, and laboratory CSF testing including the presence of oligoclonal bands (OCBs). 10 There are currently no clinical biomarkers that can predict or distinguish between different MS disease courses. 4, 11 The pathological features of MS lesions strongly support the notion that inflammation-driven mechanisms contribute to the disease. Most demyelinating sites form confluent, perivenous focal lesions observed throughout the CNS in both white and grey matter regions with variable axonal loss and reactive gliosis. 12 Spatial distribution of MS lesions is partial to periventricular, juxtacortical white matter, infratentorial areas such as the cerebellum and the pons, and short lesions of the cervical and thoracic spinal cord. 13 Lesion pathologies are heterogeneous and vary across MS patients, and are composed of mainly activated macrophages and microglia and CD8 + T lymphocytes, with smaller populations of CD4 + T cells, B lymphocytes and plasma cells 12, 14 (Figure 1 ). Although distinct neuropathological patterns have been classically defined, 14 recent recommendations have been made to classify lesions based on the distribution and contents of activated macrophages and microglia. 15 Active lesions can be temporally divided into early or late demyelinating lesions, with the latter characterised by macrophages and microglia containing the more abundant, and thus less readily cleared myelin proteins such as myelin basic protein and myelin proteolipid protein (PLP), while the former also contains these in addition to less abundant, more readily cleared proteins such as myelin oligodendrocyte glycoprotein (MOG) and myelin-associated glycoprotein. 15 Contrastingly, inactive lesions have significantly reduced numbers of macrophages and microglia, are mostly devoid of oligodendrocytes and predominate in MS patients with extended disease durations and progressive forms of MS. 15, 16 Neuromyelitis optica spectrum disorders Neuromyelitis optica spectrum disorders, previously known as Devic's disease or neuromyelitis optica (NMO), refer to a class of demyelinating syndromes characterised by the cooccurrence of inflammation in the optic nerves and spinal cord. The prevalence of NMOSD ranges between 0.5 and 4 people affected per 100 000 17 and has a significantly greater female preponderance compared to MS with a female:male ratio of up to 9:1, particularly in Afro-Caribbean populations. 18, 19 Although a subtype of MS with optic nerve and spinal cord lesions was historically identified in the Asian population, termed 'opticospinal MS', this has since been included under the diagnosis of NMOSD. 20 The age of onset of NMOSD is higher compared to MS and is rarely seen in paediatric patients. 21 NMOSD patients relapse more frequently compared to MS and accumulate greater disability as measured by median expanded disability status scale (EDSS) scores. 21 Furthermore, longitudinally extensive spinal cord lesions were more frequent in NMOSD than in MS. 21 The discovery that the large majority of NMOSD patients harboured IgG antibodies targeting the aquaporin-4 (AQP4) water channel on astrocytes has since become pivotal in NMOSD diagnosis. 22, 23 Consensus diagnostic criteria for NMOSD have been defined by Wingerchuk and colleagues in 2007 24 and refined in 2015 20 subdividing patients into AQP4 antibody (Ab)-positive or AQP4 antibody-negative NMOSD, with the former making up between 60 and 70% of NMOSD cases. 25 Core clinical characteristics defined for NMOSD include optic neuritis (ON), acute myelitis, area postrema syndrome, acute brainstem syndrome, and observation of NMOSD-typical brain lesions with diencephalic clinical syndrome and symptomatic cerebral syndrome. 20 Diagnosis of NMOSD requires the observation of at least one of the aforementioned clinical characteristics upon discovery of AQP4 Ab while more stringent diagnostic requirements need to be met if AQP4 Ab serostatus is negative or unknown. 20 The cooccurrence of other autoantibody-mediated diseases such as systemic lupus erythematosus, Sjogren's syndrome and myasthenia gravis is observed more frequently in NMOSD compared to MS and can strengthen the diagnosis of NMOSD. 20 Pathology of NMOSD lesions is driven by the binding of pathogenic AQP4 Ab on astrocytic endfeet surrounding endothelial cells and has been long identified as a demyelinating disease that is secondary to a primary astrocytopathy. 26 In contrast to the CD8 + T cell predominance in MS lesions, activated CD4 + T cells infiltrating the CNS are central mediators in NMOSD lesion formation 27 (Figure 1 ). Preferential localisation of NMOSD lesions in the spinal cord and optic nerves can be accounted for by the higher expression of AQP4 in these regions relative to the brain. 28 Lesions in NMOSD can be present with relative preservation of myelin or as classically demyelinated lesions. Demyelinated lesions are characterised by infiltration of macrophages containing myelin and astrocyte debris, marked axonal loss, astrocytic damage, decreased AQP4 expression, granulocytic inflammation, immunoglobulin and complement deposition, and vacuolated myelin. 26, 29, 30 MOG antibody-associated disease Myelin oligodendrocyte glycoprotein (MOG) has been extensively studied as a candidate autoantigen in demyelination initially because of its involvement in animal studies of experimental autoimmune encephalitis (EAE), a leading in vivo rodent model of MS. The development of assays which presented MOG in its native conformation was the first to uncover the presence of high titres of MOG Ab in paediatric demyelination cohorts, particularly prominent in children with acute Figure 1 . Pathological features of lesions in autoimmune demyelination. Demyelinating lesions commonly consist of immune cell infiltrates predominated by activated macrophages and microglia, lymphocytes, and varying degrees of immunoglobulin and complement deposition. CD4 + T cells outnumber CD8 + T cells in MOGAD and NMOSD while CD8 + T cells predominate in MS. Granulocytic infiltration is seen in MOGAD and NMOSD while not frequently observed in MS lesions. Axon and astrocyte loss is profound in NMOSD while astrocytes and axons are largely preserved in MS and MOGAD. AQP4 downregulation is observed in NMOSD while conflicting reports of MOG internalisation have been seen in MOGAD. Ab, antibody; AQP4, aquaporin-4 water channel; Ig, immunoglobulin; MOG, myelin oligodendrocyte glycoprotein; MOGAD, MOG Abassociated disease; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders. disseminated encephalomyelitis (ADEM). [31] [32] [33] [34] In particular, the live cell-based assay which involves the recombinant expression of conformational MOG on the cell surface of eukaryotic cell lines has become the gold standard detection method for MOG Ab. Further investigations using these methods revealed the presence of MOG Ab in 20-50% of adults with AQP4 Ab-negative NMOSD. 25, [35] [36] [37] This has sparked the current consensus to distinguish patients with MOG Ab as a separate disease entity from NMOSD, termed MOGAD.

Despite numerous international recommendations, determination of consensus diagnostic criteria for MOGAD is still ongoing. The typical clinical characteristics of MOGAD include ON, myelitis, and encephalitis, and these phenotypes can be monophasic or relapsing in disease course. 38 The clinical spectrum of MOGAD is continually expanding with emerging reports of MOG Ab associated with seizures and cortical encephalitis. 39 Interestingly, despite the lack of MOG expression in the peripheral nervous system (PNS), MOG Ab has been described in patients with co-existing inflammatory PNS syndromes. 40 The co-incidence of these PNS symptoms and their direct association with MOGAD warrants further investigation.

Prevalence studies involving MOGAD cohorts are scarce. In a recent UK study, the prevalence of MOGAD was approximately two per 100 000 with the female:male ratio estimated at 1.8:1, proportionally affecting more men compared to NMOSD and MS. 41 Patients with MOGAD have been reported as having less residual functional impairment compared to AQP4 Ab-positive NMOSD, 25, 42, 43 although this is not universal with some patients, particularly those with a relapsing disease course, suffering permanent visual loss or paraplegia. 44 The co-existence of MOG Ab and AQP4 Ab in the same individual is seldom reported and occurs in as low as 0.06-8% of patients with demyelination. 45, 46 A small subset of MS patients are seropositive for MOG Ab. [47] [48] [49] In contrast to MS, CSF findings in adult and paediatric MOGAD cohorts show that OCBs are less commonly observed in MOGAD compared to MS, and are seen in 10-30% of patients. 50, 51 Radiological differences highlight that MOGAD and NMOSD patients with ON are more likely to have bilateral and longitudinally extensive optic nerve lesions compared to MS patients with ON. 52 Comparatively, MOGAD patients with ON more frequently experienced lesions in the anterior visual pathway relative to NMOSD patients with ON in which lesions were observed posteriorly including the optic chiasm and optic tract. 52 Area postrema involvement is less common in MOGAD and more predominant in NMOSD. 53 Similar to NMOSD, longitudinally extensive transverse myelitis (TM) is observed in MOGAD and rarely observed in MS. 54 Short lesions of TM similar to those seen in MS also occur in MOGAD. 55 While there is currently no clinical predictor of relapse in MOGAD patients, persistent MOG Ab seropositivity has been associated with a relapsing disease course while those with transient seropositivity were more likely to be monophasic. 56, 57 MOGAD lesions are characterised by perivenous, confluent demyelination, axonal preservation, reactive astrocyte gliosis, prominent intracortical demyelination, with immune cell infiltrates, complement deposition and evidence of oligodendrogliopathy. 58,59 Granulocytes and CD4 + T cell infiltrates are observed in high frequencies in MOGAD lesions with astrocyte populations preserved and AQP4 expression sustained in contrast to NMOSD 58 (Figure 1 ). Intracortical lesions were more frequent in MOGAD than in MS and NMOSD. 58 Similar to MS, subpial demyelination was also observed in MOGAD. 58,59 Complement and Ig deposition were less frequently observed in MOGAD lesions compared to NMOSD. 59 Although AQP4 internalisation is an established pathogenic mechanism in NMOSD, some reports have observed MOG-dominant myelin loss at MOGAD lesions, 59 while others have shown evidence of complement deposition without selective loss of MOG expression. 58

While clinical presentations are similar between MS, NMOSD and MOGAD, differences in the origin of the autoimmune response in each disease remain to be explored and these have distinct implications to our understanding of each disease entity. Currently, the location of the initiating pathogenic event in demyelination remains contentious. In the 'outside-in' model, disease pathogenesis begins peripherally, in which autoreactive immune cells traffic into the CNS and elicit an autoimmune response. EAE rodent models are a classical demonstration of this, whereby demyelination is initiated through immunisation of adjuvant-administered myelin proteins resulting in expansion and activation of myelin-reactive CD4 + T cells. 60-64 The likelihood of peripheral immune-mediated pathogenesis is strengthened by large genome-wide association studies which have shown MS susceptibility to be enriched in genes associated with B and T lymphocytes, natural killer cells and microglia. 65, 66 Conversely, an 'inside-out' model posits that disease is resultant of pre-existing damage to oligodendrocytes and myelin, prompting immune cell recruitment to sites of injury, following which an inflammatory response proceeds. This is exemplified in cuprizone-induced models of demyelination which directly elicits oligodendrocyte cytotoxicity and subsequent inflammatory demyelination. 67 Furthermore, alterations to myelin-related genes support this 'inside-out' model of disease pathogenesis, as seen in PLP1 missense mutations found in a subset of MS patients and cause oligodendrocyte apoptosis. 68 While continued investigation is warranted into the compartment of disease onset, several genetic and environmental factors have been commonly investigated across these diseases.

The presence of HLA-DRB1*15:01 and the absence of HLA-A*02 have been frequently associated with a significantly increased risk of developing MS. 69 In some cases, MS has been postulated to be a neurodegenerative disorder where the inflammatory response is secondary to neurodegeneration. 70, 71 However, in a multinational genome-wide association study of 9772 cases of MS, genes relevant to inflammationindependent neurodegenerative pathways lacked an association to MS, while genes for CD4 + T cell differentiation were over-represented and implicated in disease pathogenesis. 66 In a nextgeneration sequencing study of 31 Japanese NMOSD patients, HLA-DQA1*05:03 was found to be significantly associated with NMOSD. 72 More recently, in a cohort of 165 NMOSD patients, HLA-DRB1*08:02 and HLA-DPB1*05:01 were found to be susceptibility alleles while HLA-DRB1*09:01 was found to be protective. 73 In contrast, HLA-A*01, HLA-B*08 and HLA-DRB1*03 were associated with NMOSD in a recent Dutch study while no association between HLA and MOGAD was observed. 74 This study, however, did not separate adult and paediatric MOGAD cohorts, whereas in a recent Chinese study of 95 MOGAD patients (51 paediatric, 44 adult), HLA-DQB1*05:02-DRB1*16:02 alleles were associated with paediatric onset of MOGAD while no association between adult-onset MOGAD and HLA genotype was observed. 75 Infectious prodrome Viral infection is among many environmental factors that have been commonly linked to or seemingly preceding autoimmune disease. Arguably, most renowned is the association between MS and Epstein-Barr virus (EBV) with almost all MS patients having been previously infected with EBV. 76 EBV Ab seropositivity is observed at higher rates in MS patients and is strongly correlated with disease onset. 77, 78 Additionally, EBV-induced infectious mononucleosis is found to be associated with a twofold risk of developing MS. 77 Autoreactive B cells latently infected with EBV are proposed to contribute to MS pathogenesis by evading elimination of CD8 + T cells and accumulating within the CNS, producing myelin-reactive antibodies and survival signals for T cells. 78 Induction of MOGAD by a viral infection has also been reported, with the most common occurrence observed in paediatric patients who develop ADEM following viral infection. Postinfectious MOGAD cases include HSV-1 infection followed by ADEM 79 and ON 80 and rubella infection followed by ON. 81 Up to 40% of patients experience a nonspecific viral prodrome with or without fever, prior to clinical onset. Most recently emerging, two reported cases of SARS-CoV-2 infection were followed by MOG Ab-associated ON 82 and NMOSD. 83 Despite these cases, the association between viral infection and demyelination remains unclear and leading hypotheses regarding molecular mimicry of myelin proteins because of their structural overlap with viral proteins remain largely unvalidated in humans. Other than viral infection, there is also emerging evidence regarding non-infectious clinical prodromes preceding autoimmune demyelination. Within 5 years of disease onset, patients with MS were reported to have greater fatigue, sleep disorders, anaemia and pain compared to healthy controls. 84 Neuropathic pain has been reported in MOG Aband AQP4 Ab-positive patients, 85 with another study identifying prodromal headaches in almost 50% of patients with MOG Ab-positive ON. 86 

Low vitamin D levels, insufficient UV exposure and higher latitudes have each been linked to an increased risk of developing MS. 87 In a recent study of two independent multicentre cohorts, lower disease severity was seen in MS patients with higher vitamin D levels. 88 Although UV exposure is correlated with the maintenance of sufficient levels of vitamin D, the role of sun exposure in the development of MS may be vitamin D-independent. 89 For instance, while whole-body UV irradiation of mice prevents the development of EAE, 90 UV-induced suppression of EAE was still observed in mice lacking the vitamin D receptor. 91 Interestingly, in a recent crosssectional study of 29 NMOSD patients, increased sun exposure and serum calcifediol (a vitamin D metabolite) were seen in AQP4 Ab-negative NMOSD patients compared to AQP4 Ab-positive patients, potentially implicating a role of vitamin D in AQP4 Ab synthesis. 92 Presently, associations of vitamin D and sun exposure have yet to be explored in MOGAD cohorts. 93 

A paraneoplastic association has been described in a few cases of MOGAD and AQP4 Ab-positive NMOSD and may be associated with the pathogenesis of demyelination. More recently, expression of oligodendrocyte markers, including MOG, and CD4 + and CD8 + T cell infiltration have been described in the teratoma tissue of a MOG Ab-positive ON patient with ovarian teratoma. 94 This is in contrast to the more frequently associated lung and breast adenocarcinomas in a small number of patients with NMOSD 95 ; however, cases of ovarian teratomas in NMOSD have also been reported. 96 A patient positive for CSF MOG Ab and presenting with longitudinally extensive TM, BON, and brainstem encephalitis coincidentally with lung adenocarcinoma has been recently reported 97 ; however, it is clear that the paraneoplastic nature of demyelination is rare and warrants further investigation.

Intestinal microbiota influence both local and systemic immune responses through its interaction with the gut-brain axis and offer several hypotheses regarding the origin of the autoimmune response. A recent study found that RRMS patients with active disease had increased numbers of intestinal Th17 cells, and expansion of this population was reliant on the composition of gut microbiota. 98 An increased relative abundance of anti-inflammatory Prevotella strains was seen in healthy controls and RRMS patients without active disease. 98 More recently, clonally expanded IgAexpressing B cells have been found to actively traffic to the CNS with specificity against certain phyla of gut microbiota and were detected in the CSF and tissue of active MS-associated lesions and could therefore serve as a systemic biomarker for active disease in MS. 99 Recent investigations into the involvement of gut microbiota in NMOSD pathogenesis have revealed the role of Clostridia perfringens in the disease. This strain was enriched in NMOSD patients and has been implicated in the regulation of Treg and Th17 cell populations. Specifically, AQP4-specific T cells in NMOSD patients exhibited a Th17 phenotype and cross-reacted with a C. perfringens peptide sequence. 100 A newly isolated Erysipelotrichaceae bacterium has been recently described that when co-cultured with Lactobacillus reuteri which has homology to MOG peptides, Th17 inflammatory responses were induced from MOG-specific Th17 cells and increased EAE severity. 101 Other instances of molecular mimicry to MOG have been demonstrated in a small proportion of MS patients harbouring antibodies targeting MOG peptides which cross-reacted with the bovine milk protein butyrophilin. 102 Additionally, butyrophilin has been shown to induce a MOG-specific T-cell response in rats, while also having the potential to produce a tolerogenic response and alleviate EAE. 103 As this was investigated in the context of MS, which is now known to comprise a small minority of MOG Ab-positive patients, these findings have yet to be investigated in a MOGAD cohort.

While MS has been classically considered a T celldriven disease, the efficacy of B-cell-targeted therapies has warranted recent investigation into the regulatory or antigen-presenting role of B cells. [104] [105] [106] Conversely, even though NMOSD and MOGAD have a clear antibody association, the role of antigen-specific T cells in these disorders 

The contribution of pathogenic T cells has been considerably explored in the context of MS which has been classically described as a T cell-mediated disease. In particular, in EAE, the role of CD4 + Th17 cells is well established as being the primary mediators of disease pathogenesis 107 with recent findings showing increased frequencies of distinct Th17 subsets in the blood and CSF of patients with RRMS compared to SPMS. 108 Regardless of disease course, CD8 + T cells in MS lesions far outweigh the frequency of other infiltrating lymphocytes such as B cells and CD4 + T cells. 109 CD8 + T cells are enriched in the CSF of RRMS patients early in disease, 110 and these CD8 + T cells found in the CSF shared the same repertoire as CNS-resident CD8 + T cells. 111 However, the role these CD8 + T cells play in disease is not well understood. For instance, myelin-specific CD8 + T cells from MS patients have demonstrated a proinflammatory profile when expanded in vitro and expressed CD20 in greater proportions compared to control subjects. 105 These myelinspecific CD20 + CD8 + T cells were preferentially depleted by anti-CD20 therapy which has been shown to be effective in MS treatment. 105 On the contrary, a subset of clonally expanded regulatory CD8 + T cells have been recently described to suppress the pathogenicity of CD4 + T cells in EAE, 112 and thus, CD8 + T cells may play a multifaceted role as either a regulatory or pathogenic mediator of human demyelination.

Antigen-specific T cells in NMOSD and MOGAD have been seldom detected despite central dogma for the necessity of these cells in their role for autoantibody production and pathogenicity. Interestingly, AQP4-specific CD4 + T cells were detected in AQP4 Ab-positive patients, with T cell reactivity observed in a peptide sequence at amino acids 156-170 which overlaps with the epitope recognised by AQP4 Ab. 113, 114 Contrastingly, the same study could not detect MOG-specific T cells in MOG Ab-positive patients and this was postulated to be because of the failure of synthetic peptides in mimicking antigen processing and MHC presentation. 113 Indeed, a previous study using Escherichia coli-expressed MOG coupled to fluorescent beads was able to detect MOG-specific CD4 + T cells producing IFNgamma, IL-22 and IL-17A in 16 out of 29 MS patients. 115 However, MOG Ab was detected in only one of these patients reinforcing the notion that MOG Ab seropositivity in MS patients is rare and that the role of MOG-specific T cells in MS patients remains difficult to explore. 115 Although antigen-specific T cells in demyelination have been challenging to isolate, the cytokine profile of demyelination patients implicates the role of specific T cell subpopulations. The proinflammatory Th17-related cytokines IL-6 and G-CSF were elevated in paediatric MOGAD patients compared to MOG Ab-negative patients with demyelination. 116 In a cross-sectional study, adult and paediatric MOGAD patients were found to have an upregulation of Th17, Th1-related and Treg-related cytokines. 117 These cytokines were similar to those upregulated in the CSF of AQP4 Ab-positive NMOSD patients; however, they differed significantly from MS patients. 117 

The initiation of an autoimmune response against CNS antigens can lead to the breach of the blood-brain barrier (BBB) to allow leukocyte infiltration, antibody deposition and inflammation in the local CNS region. [118] [119] [120] Autoantibodies are implicated in the exacerbation of autoantigen destruction through executing effector functions such as the activation of complement-dependent cytotoxicity (CDC) or antibody-dependent cellular cytotoxicity (ADCC). 121 Even though a central autoantigen in MS remains unidentified, evidence exists for the contribution of humoral mechanisms in disease pathogenesis in addition to the T cell-driven response. 109, 122 Intrathecal OCBs are a hallmark feature of MS, in which the presence and quantity are strongly associated with disease severity and disability in patients. [123] [124] [125] [126] [127] Several studies have evidenced the role of B cells in the production of OCBs, [128] [129] [130] thus implicating the importance of the humoral response in promoting characteristic MS demyelination. This is further supported by the observation that B cells are responsible for mediating brain homing Th1 cell autoproliferation, and B-cell depletion by anti-CD20 therapies reduces T cells and inflammation both in vitro and in patients with MS. 104 MS patients commonly display elevated intrathecal Ig, specifically IgG1 and IgG3. 131 These findings have been supported by recent studies observing higher serum IgG3 may be predictive of the progression of CIS towards MS. 132, 133 Subsequent functional assays on antibody pathogenicity in animal and human models have confirmed MS lesion observations. Injection of CSF from MS patients was observed to induce demyelination and axonal damage in mice. 134 Evidencing the specific role of antibodies in this process, recombinant IgG1 from MS patient CSF was observed to initiate CDC, rapid demyelination and microglia activation on mouse organotypic cerebellar slices. 135 In addition to CSF antibodies, serum autoantibodies have the capacity to disrupt the BBB, target brain microvessels and initiate destruction of myelin. 136 Defining a putative autoantibody responsible for MS demyelination is encumbered by the potential heterogeneity of target autoantigens in MS. Various autoantibody targets have been investigated (Table 1) . For instance, the presence of isotype-switched antibodies against myelin PLP is significantly elevated in patients with RRMS and SPMS who have specific HLA types, and PLP Ab titres correlated with disease severity. 137 Additionally, a subgroup of MS patients with brainstem and cerebellar lesions have been identified with PLP antibodies. 138 In other cases, the pathogenic potential of these autoantibodies has been evidenced through the initiation of CNS inflammation following the passive transfer to rodent models 139 ; however, validation of their pathogenic roles in humans remains unprecedented. Distinct subgroupings of MS patients with precise disease course, clinical and radiological features may facilitate discovery of new autoantigenic targets and discrete clinical entities, as has been the case for the discovery of AQP4 Ab and MOG Ab.

The mechanisms of AQP4 Ab pathogenesis have been investigated extensively through functional assays in animals and human tissue. An early in vitro study revealed that serum-derived IgG from NMOSD patients binds to astrocytes and increases BBB permeability to permit autoimmune reactivity within the CNS. 140 Further, human AQP4 Ab binding to astrocytes initiates injury, secondary oligodendrocytopathy and demyelination through CDC, ADCC or induction of inflammation through granulocyte activation. [141] [142] [143] The process by which astrocytopathy leads to demyelination in NMOSD remains unclear. Bystander formation of membrane attack complexes in the process of CDC has been shown in neurons and oligodendrocytes co-cultured with astrocytes. 144, 145 Other studies demonstrate internalisation and downregulation of the astrocytic glutamate receptor, EAAT2, alongside AQP4 upon Ab binding, 146 and have therefore implicated glutamate excitotoxicity to oligodendrocytes as a contributing factor in disease pathogenesis. 147 The production of recombinant antibodies from NMOSD patient periphery- [148] [149] [150] and CSF-derived 149, 151, 152 B cells revealed that AQP4 Ab initiates pathogenic effects both in vitro and in vivo because of defective central and peripheral B cell tolerance mechanisms. Recombinant AQP4 Ab was observed to specifically bind to the H101/L104 epitope and initiate CDC. 152 Supporting these findings, recent clinical trials indicate that eculizumab, a complement inhibitor, reduces relapse rates in patients. 153 Additionally, the IL-6 cytokine pathway has been strongly implicated in NMOSD pathogenesis [154] [155] [156] and using antibodies against the IL-6 receptor has demonstrated a strong potential to block this pathway through reducing the survival of AQP4 Ab-secreting plasmablasts. 157 Evidence of disease initiation and exacerbation following passive transfer of AQP4 Ab further outlines the pathogenic role of these autoantibodies. Immunisation with AQP4 peptides exacerbated experimental autoimmune myasthenia gravis symptoms in mice, including fatigue, weakness and decreased nerve responsiveness. 158 The administration of recombinant AQP4 Ab to rodents has provided strong evidence to support in vivo studies. Recombinant AQP4 Ab generated from NMOSD patient CSF-derived plasma cells was observed to initiate perivascular astrocyte depletion, myelinolysis, and Ig and complement deposition in EAE rats. 151 In line with functional assays on pathogenicity, the observation that seropositivity is associated with increased chances of opticospinal involvement, longitudinally extensive spinal cord lesions, relapse rate and lower EDSS scores further evidences the role of the autoantibodies in driving demyelinating pathogenesis. 159 Although the mechanism of pathogenesis initiation within the CNS is still debated, current evidence points towards a peripherally initiated response in NMOSD. For instance, intrathecal production of AQP4 Ab is rarely observed in NMOSD patients. 160 Additionally, a recent report demonstrated that Injection of AQP4 peptide to mice with experimental autoimmune myasthenia gravis aggravates disease symptoms 158 Rats immunised with mimotopes of conformational AQP4 epitopes produce AQP4 Ab detectable in sensitive cell-based assays; however, no concurrent pathology was observed 218 Encephalomyelitic syndrome was initiated when Rag1 À/À mice reconstituted with mature T cells of Relapse rate higher in MOG Ab-seropositive patients 131, 219 AQP4 Ab seropositivity is predictive of relapse and titres increase during relapse [220] [221] [222] High titres associated with increased disease activity (complete blindness or extensive CNS involvement) 223 Treatment with rituximab causes significant improvement of disease activity most patients, 224 and AQP4 Ab concentration decreases in serum after immunosuppressive therapy 222 Chimeric, high avidity AQP4 Ab blocks patient IgG binding to AQP4, thus preventing CDC in vitro 225 Coexistence of AQP4 and ANA Ab associated with more severe disease phenotypes 196 Disease ameliorated upon treatment with steroids and rituximab 44 High MOG Ab titres are predictive of a more severe, relapsing course and increase during active disease 56, 168 Ab, antibody; ADCC, antibody-dependent cellular cytotoxicity; ADEM, acute disseminated encephalomyelitis; ANA, anti-nuclear antibody; AQP4, aquaporin-4; CDC, complement-dependent cytotoxicity; CSF, cerebrospinal fluid; EAE, experimental autoimmune encephalitis; EAMG, experimental autoimmune myasthenia gravis; G-CSF, granulocyte colony-stimulating factor; HERV-W, systemic injection of AQP4 Ab has a number of entry sites into the CNS and produced NMOSDlike lesions. 161 Although some studies report the necessity for T cells in AQP4 Ab lesion formation, 162 others suggest that AQP4 Ab alone can induce NMOSD pathology without T cell help. 161 It is likely that both pathways are required in NMOSD pathogenesis, as indicated in a study which observed that while immunisation with AQP4 initiates encephalomyelitis in Rag1 À/À mice with the presence of T cells alone, lesions are only produced in the presence of both antibodies and T cells against AQP4. 163 MOG Ab has been shown to contribute to CNS demyelination through CDC or ADCC-mediated lysis of MOG-expressing cells. 31, 164, 165 These findings are supported by the observation that the majority of MOG Ab are IgG1, 33,166-169 a subclass efficient in fixing complement and binding to Fc receptors for ADCC initiation although the potency of these effector mechanisms may be dependent on autoantibody affinity. 170 Further studies suggest murine and human MOG Ab induce cytoskeleton disruption and microtubule destabilisation. 37, 171 Several studies have further observed CNS inflammation and complement-dependent lysis of MOG-expressing cells following passive transfer of high-affinity patient MOG Ab to rodents. 172, 173 A recent report demonstrated the pathogenicity of an antibody derived from the RNA of postmortem human brain tissue and showed similar demyelinating activity to a prototypical murinederived MOG Ab. 174 However, these studies use rodent-reactive antibodies which are only present in a minor proportion of MOGAD patients, with between 70 and 80% of human MOG Ab recognising a conformational epitope at position 42 of the extracellular domain of MOG where proline exists in humans as opposed to serine in rodents. 168, 175 Autoantibody pathogenicity in a primate model has since been demonstrated in an in vivo macaque model in which complementdependent vacuolisation of myelin, lesion pathology, EAE and MOG Ab were observed after injection of recombinant human MOG. 169 

With ongoing attempts to make the delineation between MS, NMOSD and MOGAD progressively clearer, discernment of the correct disease entity remains reliant on evaluation of clinical presentations and accurate paraclinical testing. Increasingly evident is the need to standardise assay methodologies for the accurate detection of demyelination-associated autoantibodies. 109, 176 Several multicentre studies over recent years have evaluated the accuracy, sensitivity and specificity of antibody testing in NMOSD and MOGAD. A multicentre study of 21 AQP4 Ab assays across 15 European centres found that cell-based assays using microscopy produced the highest sensitivities and specificities. 177 It also further reinforced the use of the M23 isoform of AQP4, with improved sensitivity in contrast to the M1 isoform, 177 attributed to findings that formation of orthogonal array of particles (OAPs) exclusive to the M23 isoform, is important for pathogenic human AQP4 Ab binding. 141 Recent validation studies have demonstrated lower concordance in MOG Ab testing when determining the presence of MOG Ab in patients with borderline and low MOG Ab titres tested across international centres. 178 Differences in assay methodologies, data analyses and cut-offs for MOG Ab positivity largely account for these discrepancies. 179, 180 Moreover, studies on the isoform of MOG have shown that C-terminal truncation of the full-length protein decreases binding of human MOG Ab 181 and is likely because of the effect of truncation on the second hydrophobic domain of MOG which has recently been revealed to be important in the bivalent binding of human MOG Ab. 170 Although major human MOG Ab epitopes have been described in the extracellular domain of the protein, 168, 175 it has been postulated that the transmembrane domains and cytoplasmic tail may play an important role in the surface expression and oligomerisation of the antigen. Further, the use of fixatives in cell-based assays has been shown to alter the native conformation of MOG and significantly decrease the sensitivity of the MOG Ab test. 168, 178 Hence, cell-based assays using live cells are the current gold standard in the detection of these antibodies, 38, 178, 182 and therefore, translation and standardisation of these assays for routine diagnostic testing are highly warranted.

Recent studies are also shedding light on the cooccurrence of disease-associated autoantibodies in CNS neurological disorders. For instance, the coexistence of NMDAR Ab and other autoantibodies associated with autoimmune encephalitis in MOGAD and AQP4 Ab-positive NMOSD patients has been observed. 183, 184 AQP4 Ab-positive NMOSD has been found to occur in patients with AChR Abpositive myasthenia gravis with NMOSD onset most commonly occurring after diagnosis of MG. 185 This was further reflected in antibody titres, with AChR Ab decreasing as AQP4 Ab increased over the disease course.

Predicting disease course remains a significant challenge as residual disability and worsening of clinical outcomes often accumulates with further relapses in MS, NMOSD and MOGAD. Intriguingly, a recent study found an association between epitope binding patterns and likelihood to relapse, with 75% of adult MOGAD patients that did not recognise the Proline42 epitope, the major immunodominant binding region of human MOG Ab, presented with a relapsing disease course. 168 This provides evidence that characterising the epitope of autoantibodies in demyelination may prove useful in predicting disease course, thereby enabling refinement of therapeutic pathways. Characterisation of binding patterns in AQP4 Ab-positive NMOSD showed a change in AQP4 Ab epitope in only a minority of patients over the disease course. 186 Similarly, the immunodominant epitope in MOGAD patients also remains stable over time. 168 Additionally, while MOGAD patients exhibited the same Ab characteristics in serum and CSF, paired CSF-serum samples containing AQP4 Ab taken at the same time exhibited different binding patterns potentially suggesting the contribution of two independent sources of antibody production in NMOSD. 186 Given the exemplars of MOG Ab and AQP4 Ab, the discovery and validation of new biomarkers may have significant implications in predicting disease features. Axonal damage is variable across demyelinating diseases and can be measured by neurofilament levels. Recent findings have shown elevated blood and CSF neurofilament levels in RRMS patients associated with disease activity, disability score and more frequent relapse. 187 Additionally, in 18 MOGAD patients followed longitudinally, elevated neurofilament light-chain levels at baseline remained stable or decreased over time, signifying peak axonal damage occurring at disease onset. 188 Interestingly, similar associations have been reported between elevated serum levels of glial fibrillary acidic protein (GFAP) 189 and NMOSD, in which higher GFAP levels were correlated with greater disability and shorter time to relapse. 190 

Evolution of new technologies such as single-cell RNA sequencing has shed light on impairments to immune tolerance checkpoints that result in CNS autoreactivity (reviewed in Zou et al. 150 ). Delivery of mRNA to lymphoid tissues in order to mimic and correct peripheral tolerance mechanisms has recently been demonstrated in an EAE mouse model. 191 In this study, vaccination using MOG peptide-encoding mRNA enabled the expansion of MOG-specific Foxp3 + Treg cells and prevented the development and worsening of symptoms in MOG-induced EAE mice. 191 Single-cell RNA sequencing revealed that the expansion of effector Tregs played a significant role in suppressing proinflammatory Th1 and Th17 cells that would otherwise cause disease. Further, the importance of PD-1 and CTLA-4, which are inhibitory receptors on activated T cells, were emphasised when blockade of these receptors abolished the protective effect of MOG mRNA vaccination. Overall, the study demonstrated the first instance of a protective mRNA vaccine in an autoimmune disease, and showed that pathogenic T cells are inhibited rather than deleted and were reliant on PD-1 and CTLA-4 signalling.

In summary, MS, NMOSD and MOGAD can present with similar and often overlapping clinical and radiological characteristics that have made the differential diagnoses of these disorders challenging. The discovery of AQP4 Ab and MOG Ab has become essential in the diagnoses of NMOSD and MOGAD, respectively. Remarkably, despite expression of these autoantigens on distinct cell types of the CNS with heterogeneous pathologies, their immunopathogenic mechanisms lead to similar clinical features. Although the pathogenic role of AQP4 Ab has been more thoroughly investigated, evidence of MOG Ab pathogenicity is emerging. While current focus lies on the autoantibodies in NMOSD and MOGAD, there remains a need to clarify the contribution of T cells in pathogenesis. Although extensive research in MS disease models has demonstrated a primary pathogenic role of CD4 + T cells, B cell and antibody ª 2021 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc involvement in MS is being investigated, with a present demand to define patient subgroups in MS with regard to specific autoantigens. Along with associations to environmental factors such as infection, vitamin D and UV exposure, advancing research in the contribution of the gut microbiome provides a potential avenue for novel therapeutic interventions and for modifiable factors involved in brain health. As immunosuppressive and immunomodulatory therapies differ in efficacy across these disorders, a deeper understanding of the aetiology and pathogenic mediators of disease is essential to determine targeted therapeutic approaches to improve treatment decision-making and patient outcomes. 

Revisiting the mechanisms of CNS immune privilege

Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Defining the clinical course of multiple sclerosis: the 2013 revisions

Assessing changes in relapse rates in multiple sclerosis

Two sides to every story: perspectives from four patients and a healthcare professional on multiple sclerosis disease progression

Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity

Progressive multiple sclerosis

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria

Biomarkers of multiple sclerosis: current findings

Multiple sclerosis pathology

Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

An updated histological classification system for multiple sclerosis lesions

Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque

Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis

Sex differences in autoimmune disorders of the central nervous system

Demographic and clinical features of neuromyelitis optica: a review

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

The clinical profile of NMOSD in Australia and New Zealand

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

The spectrum of neuromyelitis optica

Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders

The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica

Mechanisms for lesion localization in neuromyelitis optica spectrum disorders

Aquaporin 4 expression and tissue susceptibility to neuromyelitis optica

Diagnostic utility of aquaporin-4 in the analysis of active demyelinating lesions

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis

Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease

Selfantigen tetramers discriminate between myelin autoantibodies to native or denatured protein

Agedependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis

Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome

Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis

Myelinoligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype

Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton

MOG encephalomyelitis: international recommendations on diagnosis and antibody testing

Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study

Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders

Prevalence and incidence of neuromyelitis optica spectrum disorder, aquaporin-4 antibody-positive NMOSD and MOG antibody-positive disease in Oxfordshire

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study

Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study

Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination

Coexistence of myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies in adult and pediatric patients

Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD

Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis: a multicenter cross-sectional study

Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis

A multicenter comparison of MOG-IgG cell-based assays

Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: results from 163 lumbar punctures in 100 adult patients

Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: results from 108 lumbar punctures in 80 pediatric patients

Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis

Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice

Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis

MBP-induced experimental autoimmune encephalomyelitis in C57BL/6 mice

International Multiple Sclerosis Genetics C. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis

Biochemically altered myelin triggers autoimmune demyelination

PLP1 mutations in patients with multiple sclerosis: identification of a new mutation and potential pathogenicity of the mutations

Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis

Multiple sclerosis is primarily a neurodegenerative disease

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Next-generation sequencing identifies contribution of both class I and II HLA genes on susceptibility of multiple sclerosis in Japanese

HLA genotype-clinical phenotype correlations in multiple sclerosis and neuromyelitis optica spectrum disorders based on Japan MS/NMOSD Biobank data

HLA association in MOG-IgG-and AQP4-IgG-related disorders of the CNS in the Dutch population

Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort

Epstein-Barr virus and multiple sclerosis: potential opportunities for immunotherapy

Epstein-Barr Virus and multiple sclerosis

Epstein-Barr Virus in multiple sclerosis: theory and emerging immunotherapies

A case of MOG antibody-positive bilateral optic neuritis and meningoganglionitis following a genital herpes simplex virus infection

The relationship between anti-myelin oligodendrocyte glycoprotein antibody-associated disease and the Rubella Virus

Myelin oligodendrocyte glycoprotein antibodyassociated optic neuritis and myelitis in COVID-19

Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report

Fatigue, sleep disorders, anaemia and pain in the multiple sclerosis prodrome

Pain in AQP4-IgGpositive and MOG-IgG-positive neuromyelitis optica spectrum disorders

Prodromal headache in MOG-antibody positive optic neuritis

Latitude, sun exposure and vitamin D supplementation: associations with quality of life and disease outcomes in a large international cohort of people with multiple sclerosis

Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity

Sun exposure and vitamin D are independent risk factors for CNS demyelination

Prevention of experimental allergic encephalomyelitis (EAE) in the SJL/J mouse by whole body ultraviolet irradiation

UV light suppression of EAE (a mouse model of multiple sclerosis) is independent of vitamin D and its receptor

Association between sun exposure, vitamin D intake, serum vitamin D level, and immunoglobulin G level in patients with neuromyelitis optica spectrum disorder

Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases

MOG-expressing teratoma followed by MOG-IgG-positive optic neuritis

Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies

Paraneoplastic neuromyelitis optica and ovarian teratoma: a case series

Multiple intracranial lesions with lung adenocarcinoma: A rare case of MOG-IgGassociated encephalomyelitis

High frequency of intestinal T H 17 cells correlates with microbiota alterations and disease activity in multiple sclerosis

Gut microbiotaspecific IgA + B cells traffic to the CNS in active multiple sclerosis

The gut microbiome in neuromyelitis optica

Gut microorganisms act together to exacerbate inflammation in spinal cords

Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis

Butyrophilin, a milk protein, modulates the encephalitogenic T cell response to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis

Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis

Anti-CD20 therapy depletes activated myelin-specific CD8 + T cells in multiple sclerosis

B-cell therapies in multiple sclerosis

T cells in multiple sclerosis and experimental autoimmune encephalomyelitis

Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only

The compartmentalized inflammatory response in the multiple sclerosis brain is composed of tissue-resident CD8 + T lymphocytes and B cells

CSF enrichment of highly differentiated CD8 + T cells in early multiple sclerosis

Expanded CD 8 T cell sharing between periphery and CNS in multiple sclerosis

Opposing T cell responses in experimental autoimmune encephalomyelitis

Comparative analysis of T-cell responses to aquaporin-4 and myelin oligodendrocyte glycoprotein in inflammatory demyelinating central nervous system diseases

Mutagenesis of the aquaporin 4 extracellular domains defines restricted binding patterns of pathogenic neuromyelitis optica IgG

Myelin oligodendrocyte glycoprotein revisitedsensitive detection of MOG-specific T-cells in multiple sclerosis

B Cell, Th17, and neutrophil related cerebrospinal fluid cytokine/ chemokines are elevated in MOG antibody associated demyelination

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a crosssectional study and potential therapeutic implications

Unexpected role of interferon-c in regulating neuronal connectivity and social behaviour

Transcranial amelioration of inflammation and cell death after brain injury

Bypassing the blood-brain barrier

Autoantibodies in movement and psychiatric disorders: updated concepts in detection methods, pathogenicity, and CNS entry

Bar-Or A. Reassessing B cell contributions in multiple sclerosis

CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients

Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis

Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy

Oligoclonal bands predict multiple sclerosis in children with optic neuritis

Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study

Evidence for the role of B cells and immunoglobulins in the pathogenesis of multiple sclerosis

In multiple sclerosis, oligoclonal bands connect to peripheral Bcell responses

Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients

Immunoglobulin isotypes reveal a predominant role of type 1 immunity in multiple sclerosis

Higher serum immunoglobulin G3 levels may predict the development of multiple sclerosis in individuals with clinically isolated syndrome

IgG3 + B cells are associated with the development of multiple sclerosis

Transglutaminase-6 is an autoantigen in progressive multiple sclerosis and is upregulated in reactive astrocytes

Myelin-specific multiple sclerosis antibodies cause complementdependent oligodendrocyte loss and demyelination

Antibodies target microvessels in neuromyelitis optica and multiple sclerosis patients

Correlation between anti-myelin proteolipid protein (PLP) antibodies and disease severity in multiple sclerosis patients with PLP response-permissive HLA types

Correlation of blood T cell and antibody reactivity to myelin proteins with HLA type and lesion localization in multiple sclerosis

Potassium channel KIR4.1 as an immune target in multiple sclerosis

Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment

Antiaquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease

B lymphocytes in neuromyelitis optica

Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica

Complementdependent bystander injury to neurons in AQP4-IgG seropositive neuromyelitis optica

Autoantibody-induced internalization of CNS AQP4 water channel and EAAT2 glutamate transporter requires astrocytic Fc receptor

Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury

Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production

CNS Aquaporin-4-specific B cells connect with multiple Bcell compartments in neuromyelitis optica spectrum disorder

Single-cell approaches to investigate B cells and antibodies in autoimmune neurological disorders

Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab

Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica

NMO-IgG and AQP4 peptide can induce aggravation of EAMG and immune-mediated muscle weakness

The prevalence of antiaquaporin 4 antibody in patients with idiopathic inflammatory demyelinating diseases presented to a tertiary hospital in Malaysia: presentation and prognosis

Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance

Circulating AQP4-specific auto-antibodies alone can induce neuromyelitis optica spectrum disorder in the rat

Can anti-AQP4 antibody damage the blood-brain barrier?

Deletional tolerance prevents AQP4-directed autoimmunity in mice

Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis

Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination

Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases

Features of MOG required for recognition by patients with MOG antibody-associated disorders

Antibodies to myelin/ oligodendrocyte-specific

Myelinreactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen

Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein

Archeological neuroimmunology: resurrection of a pathogenic immune response from a historical case sheds light on human autoimmune encephalomyelitis and multiple sclerosis

Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases

Myelin oligodendrocyte glycoprotein antibodies in neurological disease

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica

International multicenter examination of MOG antibody assays

Effects of the positive threshold and data analysis on human MOG antibody detection by live flow cytometry

Detection of MOG-IgG by cell-based assay: moving from discovery to clinical practice

MOG cellbased assay detects non-MS patients with inflammatory neurologic disease

Live-cell based assays are the gold standard for anti-MOG-Ab testing

AQP4-IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD) coexisting with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: A case report and literature review

Overlapping demyelinating syndromes and anti-N-methyl-Daspartate receptor encephalitis

Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients

Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders

Neurofilaments as biomarkers in neurological disorders

NfL levels predominantly increase at disease onset in MOG-Absassociated disorders

Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD

Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis

Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders

Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study

Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome

A populationbased prospective study of optic neuritis

Serum antinuclear antibodies associate with worse prognosis in AQP4-positive neuromyelitis optica spectrum disorder

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

Immunological differences between classical phenotypes of multiple sclerosis

Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD

Detection of potassium channel KIR4.1 antibodies in multiple sclerosis patients

Humoral responses to diverse autoimmune disease-associated antigens in multiple sclerosis

Increased anti-KIR4.1 antibodies in multiple sclerosis: could it be a marker of disease relapse?

Lack of confirmation of anti-inward rectifying potassium channel 4.1 antibodies as reliable markers of multiple sclerosis

Lack of KIR4.1 autoantibodies in Japanese patients with MS and NMO

Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review

Multiple Sclerosis and Antibodies against KIR4.1

Novel serum autoantibodies against talin1 in multiple sclerosis: possible pathogenetic roles of the antibodies

Homogeneity of active demyelinating lesions in established multiple sclerosis

Evidence for pathogenic heterogeneity in multiple sclerosis

Pathologic heterogeneity persists in early active multiple sclerosis lesions

Multiple sclerosis: in situ evidence for antibody-and complement-mediated demyelination

Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis

Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica

Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis

Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination

Astrocytic necrosis is induced by anti-aquaporin-4 antibodypositive serum

A novel myelinassociated glycoprotein defined by a mouse monoclonal antibody

Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes

Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS

Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis

NMO-IgG predicts the outcome of recurrent optic neuritis

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica

Antiaquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre

Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders